Celgene
Clinical trials sponsored by Celgene, explained in plain language.
A biopharmaceutical company focused on cancer and inflammatory diseases, now part of Bristol-Myers Squibb.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for myeloma: phase 3 trial launches for mezigdomide combo Results expected Jan 2027 (estimated)
- First human study of BMS-986368 begins in healthy chinese volunteers Results expected Feb 2027 (estimated)
- New pill shows promise for Hard-to-Treat lymphoma Results expected Apr 2027 (estimated)
- New pill could loosen MS muscle stiffness Results expected May 2027 (estimated)
- New combo aims to tackle Hard-to-Treat myeloma Results expected May 2027 (estimated)
-
New hope for myeloma: phase 3 trial launches for mezigdomide combo
Disease control Recruiting nowThis Phase 3 trial is testing whether a new drug called mezigdomide, combined with two standard drugs (bortezomib and dexamethasone), works better than the current standard combination (pomalidomide, bortezomib, and dexamethasone) for people with multiple myeloma that has come ba…
Phase 3 • Sponsor: Celgene • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New combo aims to tackle Hard-to-Treat myeloma
Disease control Recruiting nowThis study tests two drugs, mezigdomide and elranatamab, together in people with multiple myeloma that has come back or stopped responding to prior treatments. The goal is to find the safest dose and see if the combination can shrink tumors. About 62 adults will take part in this…
Phase 1/2 • Sponsor: Celgene • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug hopes to ease transfusion burden for kids with blood disorder
Disease control Recruiting nowThis study tests a drug called luspatercept in children aged 6 to 18 with beta-thalassemia, a blood disorder that often requires regular transfusions. The goal is to see if the drug is safe and can reduce the need for transfusions or raise hemoglobin levels. The trial is still re…
Phase 2 • Sponsor: Celgene • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Blood disorder drug luspatercept gets Long-Term safety review
Disease control Recruiting nowThis study follows about 665 people with myelodysplastic syndromes, beta-thalassemia, or myelofibrosis who have already taken luspatercept in earlier trials. Researchers want to see how safe the drug is over many years by tracking side effects, disease progression, and survival. …
Phase 3 • Sponsor: Celgene • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for lymphoma: golcadomide combo enters phase 3 trial
Disease control Recruiting nowThis Phase 3 trial compares a new drug combination (golcadomide plus rituximab) against standard treatments for people with follicular lymphoma that has come back or stopped responding to at least one prior therapy. About 400 participants will be randomly assigned to receive eith…
Phase 3 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Second-Chance cell therapy for myeloma patients
Disease control Expanded accessThis program offers a special type of cell therapy (ide-cel) to people with multiple myeloma whose manufactured treatment batch didn't meet commercial standards but may still be safe and effective. Participants must be clinically stable and have no other suitable treatment option…
Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New pill could loosen MS muscle stiffness
Symptom relief Recruiting nowThis study tests an experimental oral drug, BMS-986368, for treating muscle stiffness (spasticity) in people with multiple sclerosis. About 200 participants will receive one of three doses of the drug or a placebo. The goal is to see if the drug safely reduces muscle tightness an…
Phase 2 • Sponsor: Celgene • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
New pill could calm agitation in Alzheimer's patients
Symptom relief Recruiting nowThis study tests an experimental oral medication (BMS-986368) to reduce agitation in people with Alzheimer's disease. About 120 participants will receive either a low dose, high dose, or placebo. The main goal is to see if the drug safely decreases agitated behaviors, such as pac…
Phase 2 • Sponsor: Celgene • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
Gene therapy survivors monitored for years in massive safety study
Knowledge-focused Recruiting nowThis study follows over 1,500 children and adults who previously received gene-modified T cell therapy for cancer. Researchers will track side effects, how long the modified cells last, and overall survival for up to 15 years. No new treatment is given—the goal is to understand l…
Phase 2/3 • Sponsor: Celgene • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC